Augurix: excellent results of new clinical study

Augurix has developed a range of tools for the diagnosis of celiac disease. The Simtomax family of tests is based upon a patented platform that enables seamless and rapid screening at the point of care, from whole blood, serum, plasma or saliva - and in just 10 minutes.
 
Celiac disease - also known as Coeliac Disease or Intolerance to Gluten - is an autoimmune disorder that occurs in genetically predisposed individuals due to an immune response to gluten, the storage protein of wheat, rye and barley. Celiac disease is considered to affect about 1% of the population, making it the most prevalent autoimmune disease on earth. The vast majority of those with the disease are undiagnosed. These patients are at high risk of developing serious. Simtomax is specifically designed to help medical professionals to lower the hurdle to diagnosis so that more patients know about their disease.
 
A clinical study conducted by Prof Jacques Bienvenu from CHU-Lyon Sud on a large pediatric population of 250 patients shows excellent performance of Simtomax, compared to the reference analyses usually run in laboratories. The study has been published in the European Journal of Gastroenterology&Hepatology.
 
Augurix was founded in 2007 and received the CTI Start-up Label in 2008. The company is based in Monthey.